Pietro P Sanna

US Patent:

6376170, Apr 23, 2002

Filed:

Nov 18, 1997

Appl. No.:

08/972564

Inventors:

Dennis R. Burton - La Jolla CA
Roberto Burioni - Del Mar CA
R. Anthony Williamson - Del Mar CA
Pietro P. Sanna - San Diego CA

Assignee:

The Scripps Research Institute - La Jolla CA

International Classification:

C12Q 170

US Classification:

435 5, 435 791, 436518

Abstract:

The present invention provides a novel method for the identification and clonal isolation of antibodies that bind to unique epitopes. The method is based on the use of antibodies as solid phase capture reagents to bind a known capture antibody epitope, thereby precluding the capture antibody epitope from being presented to a population of antibodies to be screened. The method is particularly suited for screening libraries of cloned antibodies, such as phage display combinatorial antibodies. An antibody specific for herpes simplex virus (HSV), was employed as a model for the assay.

US Patent:

7060799, Jun 13, 2006

Filed:

Feb 19, 2002

Appl. No.:

10/079802

Inventors:

Dennis R. Burton - La Jolla CA, US
Roberto Burioni - Del Mar CA, US
R. Anthony Williamson - Del Mar CA, US
Pietro P. Sanna - San Diego CA, US

Assignee:

The Scripps Research Institute - La Jolla CA

International Classification:

C12P 21/08
C12Q 1/70

US Classification:

5303873, 5303883, 5303885, 5303884, 5303888, 435 5, 436518

Abstract:

The present invention provides a novel method for the identification and clonal isolation of antibodies that bind to unique epitopes. The method is based on the use of antibodies as solid phase capture reagents to bind a known capture antibody epitope, thereby precluding the capture antibody epitope from being presented to a population of antibodies to be screened. The method is particularly suited for screening libraries of cloned antibodies, such as phage display combinatorial antibodies. An antibody specific for herpes simplex virus (HSV), was employed as a model for the assay.

US Patent:

8119854, Feb 21, 2012

Filed:

Nov 21, 2006

Appl. No.:

12/085381

Inventors:

Pietro Paolo Sanna - San Diego CA, US

International Classification:

A01K 67/00

US Classification:

800 9

Abstract:

The invention provides methods of preventing or treating drug addiction, or ameliorating the craving for an addictive drug, as well as compounds, peptides, and pharmaceutical compositions that may be used to prevent or treat drug addiction or ameliorate the craving for an addictive drug. The invention also provides methods for identifying agents that may be used to prevent or treat drug addiction, or ameliorate the craving for an addictive drug.

US Patent:

20060034800, Feb 16, 2006

Filed:

Jun 10, 2005

Appl. No.:

11/149937

Inventors:

Pietro Sanna - San Diego CA, US
George Koob - Encinitas CA, US
Serge Ahmed - Bordeaux, FR

International Classification:

A61K 38/20
A61K 38/17

US Classification:

424085200, 514012000

Abstract:

The present invention is directed to a method for treatment of drug addiction and screening methods for identifying pharmaceutical agents that ameloriate or prevent the deleterious effects of addition. The invention is as well directed to a group of genes and a group of gene products that are up or down requested as a result of addiction.

US Patent:

20110135645, Jun 9, 2011

Filed:

Oct 4, 2007

Appl. No.:

12/311587

Inventors:

R. Anthony Williamson - La Jolla CA, US
Zhifeng Chen - Vista CA, US
Pietro Paolo Sanna - San Diego CA, US
Dennis R. Burton - La Jolla CA, US
James Crowe - Nashville TN, US
John V. Williams - Nashville TN, US

Assignee:

The Scripps Research Institute - La Jolla CA

International Classification:

A61K 39/395
C07K 16/10
G01N 33/68
C12Q 1/70
A61P 31/14
A61P 37/04

US Classification:

4241371, 5303875, 5303913, 5303873, 436501, 4241591, 435 5

Abstract:

The present invention discloses methods for generating antibodies to human metapneumovirus (HMPV) polypeptides, including antibodies that immunospecifically bind to a HMPV F-protein. The invention also discloses methods for preventing, treating, or ameliorating symptoms associated with HMPV infection.

US Patent:

20120174240, Jul 5, 2012

Filed:

Jan 11, 2012

Appl. No.:

13/348596

Inventors:

Pietro P. SANNA - San Diego CA, US

International Classification:

A61K 49/00

US Classification:

800 3, 424 92

Abstract:

The invention provides methods of preventing or treating drug addiction, or ameliorating the craving for an addictive drug, as well as compounds, peptides, and pharmaceutical compositions that may be used to prevent or treat drug addiction or ameliorate the craving for an addictive drug. The invention also provides methods for identifying agents that may be used to prevent or treat drug addiction, or ameliorate the craving for an addictive drug.

US Patent:

61563137, Dec 5, 2000

Filed:

May 6, 1997

Appl. No.:

8/852147

Inventors:

Dennis R. Burton - La Jolla CA
Robert A. Williamson - Del Mar CA
Roberto Burioni - Fermignano, IT
Pietro Paolo Sanna - San Diego CA

Assignee:

The Scripps Research Institute - La Jolla CA

International Classification:

C07K 1608
A61K 39395
G01N 3353

US Classification:

4241471

Abstract:

The present invention describes human monoclonal antibodies which immunoreact with Herpes simplex virus Type-1 and Type-2. Also disclosed are immunotherapeutic and diagnostic methods of using the monoclonal antibodies, as well as nucleic acids and cell lines for producing the monoclonal antibodies.

US Patent:

20190382462, Dec 19, 2019

Filed:

Jan 12, 2018

Appl. No.:

16/477613

Inventors:

Pietro P. SANNA - San Diego CA, US
Linda S. LLOYD - San Diego CA, US

International Classification:

C07K 14/575
C07K 14/72

Abstract:

Disclosed are engineered corticotropin-releasing factor (CRF) antagonist agents, including engineered corticotropin-releasing factor (CRF) binding agents. The CRF antagonist agents and binding agents can be used to neutralize excess CRF in vivo and comprise a polypeptide having CRF-specific binding activity under physiological conditions coupled to one or more half-life-extending moieties. Pharmaceutical compositions are disclosed containing the CRF binding agents, which can be used in methods of treatment for diseases, disorders, or conditions involving hypothalamic pituitary adrenal (HPA) axis hyperactivity. Also disclosed are engineered nucleic acids (e.g., expression constructs or vectors) encoding the CRF binding agents and recombinant host cells comprising the engineered nucleic acids.